High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Oscar Health (OSCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OSCR, SNDR and TFII made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 23rd, 2026.
LCUT, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 23rd, 2026.
Insurance stocks can be well positioned in a higher interest rate environment, particularly because insurers collect premiums upfront and invest that money until claims are paid.
WOOF, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 21st, 2026.
WOOF, ARW and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 17th, 2026.
Centene's diversified market presence, cash generation and recent share gains give it an edge over Oscar Health as ACA insurers target long-term growth.
VLO, SNDR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 15th, 2026.
Here is how Oscar Health, Inc. (OSCR) and Amerant Bancorp Inc. (AMTB) have performed compared to their sector so far this year.
Apple, which just unveiled its first foldable iPhone and two other new models that go on sale this week, and Taiwan Semiconductor Manufacturing, which makes the chips that power them, lead this weekend's watch list of five top stocks near buy points. Joining AAPL and TSM are cloud-based communications software platform Twilio and two healthcare plays. Oscar Health is the No. 2 health insurer based on Affordable Care Act exchange membership.
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
BMA, ATI, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 4, 2026.
Oscar Health's membership jumps 46% to 2.96 million, but seasonal enrollment and medical utilization keep profitability in focus.
OSCR, LQDT and GEO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 2, 2026.
LCUT, CURI, OSCR, CTOS and CHYM have been added to the Zacks Rank #1 (Strong Buy) List on September 2, 2026.
SNDR, NESR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 28th, 2026.
SNDR, NESR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 26th, 2026.
SNDR, NESR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 24th, 2026.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
SNDR, NESR and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 20th, 2026.
Oscar Health CEO Mark Bertolini identified uncovered GLP-1 drugs as a potential use case for Hims on the marketplace.
Oscar Health (OSCR) is back in focus after reporting second quarter 2026 results that swung from a loss to net income of $361.81 million and raising full year earnings guidance. See our latest analysis for Oscar Health. Oscar Health shares have been volatile around the earnings release, with an 11.9% drop reported after the outlook update. The stock still shows a 118.84% year to date share price return and a 109.46% 1 year total shareholder return, suggesting momentum remains strong despite...
MTCH, PBI, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 14, 2026.
MTCH, PBI, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 12, 2026.
Oscar Health reported second-quarter 2026 results showing a shift from a prior-year loss to net income of US$361.81 million and lifted its full-year 2026 guidance to total revenue of US$18.70–US$19.00 billion and earnings from operations of US$500–US$700 million. This combination of a profit turnaround and a sizeable upgrade to operating earnings expectations suggests Oscar’s underlying operations are running more efficiently than previously anticipated. We’ll now examine how Oscar’s...
Oscar Health (OSCR) delivered earnings and revenue surprises of +155.81% and -0.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Health insurance company Oscar Health (NYSE:OSCR) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 70.4% year on year to $4.88 billion. Its GAAP profit of $1.10 per share was significantly above analysts’ consensus estimates.
SANM, OSCR and PENN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 6th, 2026.
S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. CNC stock initially moved higher, but shares reversed sharply lower as the company discussed its outlook, including slightly higher Medicaid attrition and a more costly covered population in the second half of 2026. Centene posted Q2 earnings of $2.51 a share, crushing forecasts of $1.09 by $1.42 a share.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
